Intra-Cellular TherapiesITCI
ITCI
About: Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
Employees: 561
0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
76% more call options, than puts
Call options by funds: $29.3M | Put options by funds: $16.6M
43% more funds holding in top 10
Funds holding in top 10: 7 [Q2] → 10 (+3) [Q3]
6% more repeat investments, than reductions
Existing positions increased: 132 | Existing positions reduced: 125
4% more capital invested
Capital invested by funds: $6.95B [Q2] → $7.26B (+$310M) [Q3]
2.35% less ownership
Funds ownership: 96.11% [Q2] → 93.75% (-2.35%) [Q3]
6% less funds holding
Funds holding: 370 [Q2] → 348 (-22) [Q3]
31% less first-time investments, than exits
New positions opened: 43 | Existing positions closed: 62
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$100
21%
downside
Avg. target
$124
2%
downside
High target
$132
4%
upside
4 analyst ratings
0 positive
0%
4 neutral
100%
0 negative
0%
Canaccord Genuity Sumant Kulkarni 31% 1-year accuracy 10 / 32 met price target | 4%upside $132 | Hold Downgraded | 31 Jan 2025 |
RBC Capital Brian Abrahams 17% 1-year accuracy 13 / 77 met price target | 4%upside $132 | Sector Perform Downgraded | 22 Jan 2025 |
Piper Sandler David Amsellem 63% 1-year accuracy 25 / 40 met price target | 4%upside $132 | Neutral Downgraded | 14 Jan 2025 |
Needham Ami Fadia 51% 1-year accuracy 84 / 165 met price target | 21%downside $100 | Hold Downgraded | 13 Jan 2025 |
Financial journalist opinion
Based on 23 articles about ITCI published over the past 30 days
Positive
CNBC
2 weeks ago
Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?
Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and Goliath dynamic” in 2024, report says.
Negative
Benzinga
2 weeks ago
Top 4 Health Care Stocks You May Want To Dump In Q1
As of Jan. 21, 2025, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Neutral
PRNewsWire
2 weeks ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN and ITCI on Behalf of Shareholders
NEW YORK , Jan. 16, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Enfusion, Inc. (NYSE: ENFN)'s sale to Clearwater Analytics for $5.85 per share in cash and $5.40 per share in Clearwater Class A Common Stock. If you are an Enfusion shareholder, click here to learn more about your rights and options.
Neutral
Zacks Investment Research
3 weeks ago
Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer
JNJ is set to acquire ITCI for $132 per share in cash. The transaction is likely to close before this year's end.
Positive
Zacks Investment Research
3 weeks ago
Intra-Cellular (ITCI) Moves 34.1% Higher: Will This Strength Last?
Intra-Cellular (ITCI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Neutral
Business Wire
3 weeks ago
INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Intra-Cellular Therapies, Inc. (NasdaqGS: ITCI) to Johnson & Johnson (NYSE: JNJ). Under the terms of the proposed transaction, shareholders of Intra-Cellular will receive $132.00 in cash for each share of Intra-Cellular that they own. KSF is seeking to determine whether this consideration and the process t.
Neutral
Business Wire
3 weeks ago
Shareholder Alert: Ademi LLP investigates whether Intra-Cellular Therapies, Inc. is obtaining a Fair Price for its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Intra-Cellular Therapies (Nasdaq: ITCI) for possible breaches of fiduciary duty and other violations of law in its transaction with Johnson & Johnson. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Intra-Cellular Therapies stockholders will receive only $132.00 per share in cash.
Positive
WSJ
3 weeks ago
Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal
Pharmaceutical giants have recently shown new enthusiasm for mental-health treatments with vast but unrealized promise.
Positive
Zacks Investment Research
3 weeks ago
ITCI Stock Rises 15% on Settling Caplyta Patent Litigation With Sandoz
Intra-Cellular stock gains 15% as it settles Caplyta patent litigation with Sandoz protecting the drug's exclusivity in the United States till July 1, 2040.
Positive
Reuters
3 weeks ago
Drugmakers rush to sign deals on first day of industry conference
Drugmakers signed deals worth at least $18 billion in combined value on Monday, the first day of the healthcare industry's top conference in San Francisco.
Charts implemented using Lightweight Charts™